Wilson’s Disease Drugs Market By Indication (Hepatic, Neuropsychiatric, Ophthalmic And Others), By Drug Class (Chelators, Minerals, Pipeline Analysis) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025
Wilson’s disease occurs equally in both male and female population, but research studies have cited differences in the sex specific phenotypes. Hepatic symptoms occurs 55%-60% more in the female population. Frank psychosis is more prevalent in the male population which is often mistaken as a bipolar disorder or schizophrenia. In the near future gene therapy can be used to transfer ATPB7 gene if sufficient transgene of ATPB7 is expressed in the liver cells for longer duration of time. It is very important for the accurate diagnosis of Wilson’s disease or could lead to fatal consequences if not done appropriately.
The early diagnosis of Wilson’s disease is primarily based on the multiple indications such as hepatic, neuropsychiatric, ophthalmic and others. The chelators are the first line of therapy which includes Penicillamine and trientine. Zinc acetate is considered as the only mineral prescribed for the patients that are resistant to chelators therapy. Data mining and market estimation is covered in the scope of the report to understand the opportunity for novel drug discovery in the treatment of Wilson’s disease.
Wilson’s disease comprises of geography segment which includes the major regions and their respective countries:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of LATAM
- Middle East and Africa
- GCC\
- Rest of Middle East and Africa
Market estimation and data mining is helpful in understanding the current treatment regimen and regulatory norms prevalent in different geographical regions.
Attractive investment proposition gives genuine understanding of the disease prevalence in different countries through data mining and the approach adopted to consider the treatment regimen for Wilson’s disease. Product portfolio gives an idea about the different dietary supplements enriched in zinc primarily used for the management of Wilson’s disease. Recent news coverage helps us to understand the strategic partnership taking place in the healthcare segment to lunch novel drug discovery for the treatment of Wilson’s disease. The manufacturers that are active in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc. and Wilson Therapeutics AB.
Based on Indication, the global Wilson’s disease drugs market is categorized into
- Hepatic
- Neuropsychiatric
- Ophthalmic
- Others (Heart and Kidney Complications)
Wilson’s disease is a rare hereditary disorder which occurs due to the accumulation of copper in different body organs such as liver, brain, eyes and other vital organs. The disease takes place due to the mutation in ATP7B gene. The prevalence rate of Wilson’s disease is 1 in 30,000 persons, usually diagnosed in young and adult age group. Hepatic indications are first diagnosed in the disease manifestation of Wilson’s disease on account of reduced biliary excretion of copper results in excessive accumulation of copper in liver. The early symptoms manifested in liver indications are tiredness, hepatitis with elevated levels of gamma-glutamyl transpeptidase, alanine aminotransferase and aspartate aminotransferase. The neuropsychiatric symptoms are manifested in the later stages of the disease manifestation with the basal ganglia hampering the coordinate movement. The major symptoms are Parkinsonism, tremors, ataxia, dystonia and seizures. In approximately 90 % of the patients exhibiting neuropsychiatric symptoms shows the development of Kayser-Fleishcer rings (deposition of copper) in the cornea region of the eyes. The manufacturers that are active in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc. and Wilson Therapeutics AB.
Based on drug class, the Wilson’s disease drugs market is categorized into:
- Chelators
- Penicillamine
- Trientine
- Minerals
- Zinc Acetate
The primary diagnosis of Wilson’s disease is complicated as the symptoms are similar to other diseases such as hepatitis C, seizures, jaundice, heavy metal poisoning and cerebral palsy. Even though Wilson’s disease is a genetic hereditary disease but a person is not likely to acquire the ATPB7 mutation on receiving only one abnormal gene from either of the parents. The disease management is entirely focused on compensating for the abnormal copper metabolism. As if now the chelators are the first line of treatment for achieving symptomatic relief in patients suffering with Wilson’s disease. Chelators deplete the excessive copper levels in the body by expediting their excretion through urine, but being nonspecific to copper they bind and excrete other micronutrients form the body. The adverse effects related to chelators are severe such as bone marrow suppression and kidney complications thereby hampering its market growth. Zinc acetate is the only mineral recommended as an alternative therapy to chelators. It works by reducing the dietary uptake of copper in the gastrointestinal tract and excretes it through feces. Its effect are extremely slow therefore used for maintenance therapy only.
For the purpose of this study, the global Wilson’s disease drugs market is categorized into the following regional and country specific markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
According to the U.S. Department of Health and Human Services in 2015 countrywide survey the prevalence of Wilson’s disease in the United States is 1 in 55,000 births with the Wilson’s disease allele frequency rate of 0.00428. North America is the most significant market in the Wilson’s disease treatment drugs market on account of high Wilson’s disease heterozygote frequency rate of 0.855% in the Caucasian population. The autosomal recessive rate of Wilson’s disease is approximately 25% in Europe with patients being resistant to chelators therapy and E.U. approving only zinc acetate for Wilson’s disease management in Europe. Being an orphan disease the European Medical Agency is proactively investing in the novel drug discovery for Wilson’s disease. The neuropsychiatric indications related to Wilson’s disease are on a rise in Asia Pacific. The market is heavily dependent on treatment drugs imported from U.S. and Europe which creates a huge opportunity for the existing generic market in Asia Pacific.
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Wilson’s Disease Treatment Drugs Market Portraiture
2.1.1. Global Wilson’s Disease Treatment Drugs Market, by Indication, 2016 (Value %)
2.1.2. Global Wilson’s Disease Treatment Drugs Market, by Drug Class, 2016 (Value %)
2.1.3. Global Wilson’s Disease Treatment Drugs Market, by Geography, 2016 (Value %)
Chapter 3. Wilson’s Disease Treatment Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Wilson’s Disease Drugs Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape : Global Wilson’s Disease Drugs Market, by Key Players, 2015-2025 (US$ Mn)
Chapter 4. Global Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market, by Indication, 2016
4.3. Hepatic
4.4. Neuropsychiatric
4.5. Ophthalmic
4.6. Others (Heart and Kidney Complications)
Chapter 5. Global Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market, by Drug Class, 2016
5.2. Chelators
5.2.1. Penicillamine
5.2.2. Trientine
5.3. Minerals
5.3.1. Zinc Acetate
5.4. Pipeline Analysis
5.4.1. Phase III Drug
5.4.1.1. WTX101 (bis-choline tetrathiomolybdate)
Chapter 6. Global Wilson’s Disease Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.2.1. North America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.2.2. North America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.3. North America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.3.1. Europe Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.3.2. Europe Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.3. Europe Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of Asia Pacific
6.5. Latin America Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.5.1. Latin America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.6.1. Middle East and Africa Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.6.2. Middle East and Africa Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.3. Middle East and Africa Wilson’s Disease Drugs Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East and Africa
Chapter 7. Company Profiles
7.1. Kadmon Holdings, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Merck & Co.
7.3. Noble Pharma Co., Ltd.
7.4. Teva Pharmaceutical Industries Limited
7.5. Tsumura & Co.
7.6. Valeant Pharmaceuticals International, Inc.
7.7. VHB Life Sciences, Inc.
7.8. Wilson’s Therapeutics AB
TABLE 1 Global Wilson’s Disease Drugs Market Portraiture
TABLE 2 Global Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 3 Global Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 Global Chelators Market for Wilson’s Disease Drugs, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 Global Minerals Market for Wilson’s Disease Drugs, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Global Wilson’s Disease Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 7 North America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 8 North America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 North America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Europe Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 11 Europe Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 12 Europe Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Asia Pacific Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 14 Asia Pacific Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 15 Asia Pacific Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 16 Latin America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 17 Latin America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 18 Latin America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 19 Middle East and Africa Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 20 Middle East and Africa Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 21 Middle East and Africa Wilson’s Disease Drugs Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 22 Kadmon Holdings, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Noble Pharma Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Teva Pharmaceutical Industries Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Tsumura & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 VHB Life Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Wilson Therapeutics AB: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Wilson’s Disease Drugs: Market Segmentation
FIG. 2 Global Wilson’s Disease Drugs Market Share, by Indication, 2016 (Value %)
FIG. 3 Global Wilson’s Disease Drugs Market Share, by Drug Class, 2016 (Value %)
FIG. 4 Global Wilson’s Disease Drugs Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Hepatic Indications Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 8 Global Neuropsychiatric Indications Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 9 Global Ophthalmic Indications for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 10 Global Other Indications Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 11 Global Penicillamine Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 12 Global Trientine Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 13 Global Zinc Acetate Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 14 U.S. Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 15 Canada Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 16 U.K. Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 17 Germany Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Rest of Europe Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 Japan Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 China Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 India Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Asia Pacific Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 Brazil Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Mexico Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 Rest of Latin America Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 GCC Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Middle East and Africa Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)